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There are limited data on contemporary outcomes for women with sickle
cell disease (SCD) in pregnancy. We conducted a single-site matched
cohort study, comparing 131 pregnancies to women with SCD between
2007 and 2017 to a comparison group of 1310 pregnancies unaffected by
SCD. Restricting our analysis to singleton pregnancies that reached
24 weeks of gestation, we used conditional Poisson regression to estimate
adjusted risk ratios (aRRs) for perinatal outcomes. Infants born to mothers
with SCD were more likely to be small for gestational age [aRR 169, 95%
confidence interval (CI) 113–248], preterm (aRR 262, 95% CI 182–378)
and require Neonatal Unit (NNU) admission (aRR 359, 95% CI 218–
590). Pregnant women with SCD were at higher risk of pre-eclampsia/
eclampsia (aRR 353, 95% CI 200–624), more likely to receive induction
of labour (aRR 250, 95% CI 182–176) and caesarean birth (aRR 144,
95% CI 118–176). In analysis stratified by genotype, the risk of adverse
outcomes was highest in haemoglobin SS (HbSS) pregnancies (n = 80).
There was no strong evidence that haemoglobin SC (HbSC) pregnancies
(n = 46) were at higher risk of preterm birth, caesarean delivery, or NNU
admission. Pre-eclampsia/eclampsia was more frequently observed in HbSC
pregnancies. Despite improvements in the care of pregnant women with
SCD, the increased risk of adverse perinatal outcomes remains.
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Introduction
Sickle cell disease (SCD) is the most common serious
haemoglobinopathy and one of the most common single
gene defects worldwide, affecting ˜3 million individuals and
>300 000 children are born with the condition annually.
Over the last 40 years, dramatic improvements in the sur-
vival of individuals with SCD in high-income settings has led
to the re-framing of SCD as a chronic condition with wide-
ranging implications for health in adulthood.1 Pregnancy in
women with SCD is known to be associated with an
increased risk of maternal, fetal and sickle complications.2,3
Two recent meta-analyses pooled results from comparative
studies focussing on the association between SCD and preg-
nancy; both reviews reported a fourfold increased risk of
stillbirth in pregnancies complicated by SCD.4,5 Additionally,
these reviews reported that the incidence of preterm birth,
pre-eclampsia and small for gestational age (SGA) were all
two- to four-times higher in pregnancies to women with
SCD. However, the poor methodological quality of many
previous studies has been noted, particularly the lack of
information provided on the clinical management of SCD,
the inability to stratify outcomes by SCD genotype, and the
challenge in accounting for confounding by maternal charac-
teristics.5 A study conducted using the UK Obstetric Surveil-
lance System (UKOSS) attempted to address some of these
limitations, collecting data on 109 pregnancies in women
with SCD between 2010 and 2011, and comparing the inci-
dence of perinatal outcomes to national data on all pregnan-
cies.2 Although this study largely confirmed findings from
previous reviews, the authors noted that a limitation of their
study was the inability to use a more appropriate comparison
group.
In the UK there are 100–200 births to women with SCD
each year,2 and although this forms a small proportion of
the maternity population, these pregnancies are associated
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with high healthcare utilisation and costs. In 2011, the UK
Royal College of Obstetricians and Gynaecologists (RCOG)
published a guideline for the management of SCD in preg-
nancy.6 This guideline, which has recently been updated,7
provides the basis for best practice care in the UK and rec-
ommends multidisciplinary care through joint obstetric-
sickle clinics, prophylactic folic acid to improve anaemia,
penicillin to reduce risk of infection, and low-dose aspirin.
The paucity of contemporary data on outcomes in pregnant
women with SCD in the UK means it is unclear to what
extent standardised clinical care over the last 10–15 years has
ameliorated the increased risks associated with SCD in preg-
nancy.
We compiled a retrospective cohort of pregnancies in
women with SCD receiving maternity care between 2007 and
2017 at a tertiary referral centre in London, UK. Drawing on
a matched comparison group from the general maternity
population, we aimed to assess perinatal outcomes of SCD in
pregnancy in a contemporary setting with evidence-based
optimal clinical management.
Patients and methods
Study design and population
This was a matched cohort study based on women receiving
maternity care at Guy’s and St Thomas’ NHS Foundation
Trust (GSTT) between 2007 and 2017. The GSST is a large
tertiary referral hospital in London, UK, serving a diverse
deprived inner-city population. The hospital has been run-
ning a specialist sickle-obstetric service since 2005, and the
service leads have been closely involved in the development
of the UK guidelines on SCD in pregnancy.6,7 Over the study
period, care for pregnant women with SCD at this centre
was closely aligned to the 2011 UK RCOG guideline.6 Briefly,
standard management includes daily aspirin (75–150 mg)
from pregnancy confirmation until 36 weeks of pregnancy,
and prophylactic anticoagulation as per the RCOG guide-
line.6 Most women receive blood transfusion ad hoc during
pregnancy due to clinical indications (e.g. sickle cell crisis or
severe anaemia) and prophylactic exchange is reserved for
those who are already on exchange transfusion prior to preg-
nancy, multiple pregnancies, or those with previous poor
obstetric or medical history. On confirmation of pregnancy,
folic acid (5 mg daily) and prophylactic penicillin is initiated
if the woman is not already taking these. Due to the
increased risk of stillbirth, induction of labour (or elective
caesarean if indicated) is recommended at 38–40 weeks.
Non-steroidal anti-inflammatory drugs are the preferred
method of pain relief in the postnatal period.
In this study, we included all singleton pregnancies to
women with SCD who received antenatal care at the centre.
For each SCD pregnancy, we randomly selected 10 singleton
pregnancies unaffected by SCD but receiving care at the same
hospital, matched on broad maternal ethnic category (Black,
Asian, White, Mixed, Other) and delivery year. Pregnancies
with known sickle cell trait (HbAS) were excluded as
potential comparison pregnancies given the uncertainty
regarding whether these pregnancies are also at increased
risk of adverse perinatal outcome8; pregnancies to women
with other (non-sickle) haemoglobinopathies were also
excluded. Approximately 17% of pregnancies potentially eli-
gible to be selected as comparison pregnancies had missing
data on one or more covariate and/or outcomes, these were
excluded from the selection process. Additionally, we
excluded from both the SCD pregnancy cohort and compar-
ison group any pregnancy that ended before 24 gestational
weeks, and pregnancies which ended in termination at any
gestational age.
Data sources and outcomes
Relevant data were extracted from electronic maternity
records, supplemented by manual abstraction from clinical
records for SCD pregnancies. We recorded sociodemographic
characteristics for all pregnancies: maternal age at delivery,
ethnic group, parity, body mass index (BMI), smoking status
at booking, and gestation at the initiation of antenatal care.
Area deprivation was measured using the Index of Multiple
Deprivation (IMD) for England quintiles, using 2010 scores
for pregnancies during the period 2007 to 2011,9 and IMD
2015 for pregnancies from 2012 onwards.9 For SCD pregnan-
cies we collected information on the SCD genotype.
Adverse perinatal outcomes of interest were maternal
death, stillbirth (fetal death ≥24 weeks and before birth),
pre-eclampsia/eclampsia (raised blood pressure >140/
90 mmHg with significant proteinuria), and preterm birth
(<34 or <37 weeks completed gestation). Infant outcomes
were SGA (<10th centile for gestation and sex-specific birth-
weight) and infant admission to the Neonatal Unit (NNU).
Additionally, we collected information on induction of
labour, caesarean delivery (emergency or elective), and post-
partum haemorrhage (blood loss ≥1000 ml).
Statistical analysis
We conducted descriptive analysis reporting outcomes by
SCD status. To reflect the matched cohort design, we used
conditional Poisson regression with robust variance estima-
tors to estimate unadjusted and adjusted risk ratios (RRs) for
the association between SCD and perinatal outcomes.10,11
Our primary analysis used the combined SCD group, with
additional analysis of pregnancies to women with the two
main genotypes (HbSC and HbSS) separately. The reference
group was always pregnancies unaffected by SCD. We
adjusted for the following a priori covariates: maternal age,
parity, BMI, and smoking status. Regression modelling was
restricted to outcomes where there was a minimum of two
events reported in both the SCD and comparison group. As
a sensitivity analysis, all analyses were repeated using
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generalised linear models fitted using a Poisson distribution
with a log link function, ignoring the matched design and
instead additionally adjusting for year of delivery. We used
manual abstraction of data from medical records to minimise
missing data, and we conducted a complete-case analysis.
Analyses were performed using Stata version 16 (Stata Corp.,
College Station, TX, USA).
Ethical approval
This study received approval from the London School of
Hygiene and Tropical Medicine Observational Research
Ethics Committee (Ref. 15407-1).
Results
We identified 131 eligible singleton pregnancies to women
with SCD during the 10-year time period. Of these pregnan-
cies, 80 (611%) were to women with HbSS genotype, 46
(351%) were to women with HbSC genotype, and five
(38%) were to women with HbSB+ genotype. Matching at a
ratio of 10:1, we included 1310 singleton pregnancies to
women without SCD who received care during the same per-
iod.
Maternal characteristics for these pregnancies are presented
in Table I. All SCD pregnancies were to women of Black eth-
nicity, comparison pregnancies were matched using this broad
ethnic grouping. Maternal age, parity, area-based deprivation
category (IMD), and smoking status were all similarly dis-
tributed across the comparison and SCD pregnancies. There
was a notable difference in BMI, with a higher proportion of
maternal overweight/obesity in comparison pregnancies com-
pared to SCD pregnancies (591% vs. 382%), with an even
lower proportion of maternal overweight/obesity in HbSS
pregnancies (225%). Women with SCD were more likely to
initiate antenatal care early in pregnancy: nearly one quarter
(221%) of SCD pregnancies involved an antenatal booking
appointment before 10 weeks of pregnancy, compared to
154% of comparison pregnancies.
Among the SCD pregnancies there was one stillbirth
(08%) and one maternal death (08%), both in pregnancies
affected by HbSS (Table II). In the comparison cohort there
were five stillbirths (04%) and no maternal deaths.
One in five (198%) newborns of women with SCD were
SGA. This was reflected in an adjusted RR (aRR) of 169
[95% confidence interval (CI) 113–248] for all SCD preg-
nancies compared to unaffected pregnancies (Fig 1,
Table SI). When stratifying by genotype, there was a signifi-
cant increased risk of SGA for HbSC pregnancies, but not
for HbSS pregnancies (Fig 2).
Preterm birth (<37 weeks) was higher in SCD pregnancies
compared to comparison pregnancies (198% vs. 73%; aRR
262, 95% CI 182–378). When stratified by SCD genotype,
the risk was highest for HbSS pregnancies (aRR for HbSS
293, 95% CI 180–479; aRR for HbSC 166, 95% CI 089–
308). In all, 6% of infants born to mothers without SCD
required admission to the NNU compared to 183% of
infants born to mothers with SCD (aRR 359, 95% CI 218–
590). The risk of NNU admission in HbSC pregnancies was
not significantly increased (aRR 208, 95% CI 077–564), but
the risk for HbSS pregnancies remained elevated (aRR 548,
95% CI 290–1038) (Fig 2).
The proportion of SCD pregnancies complicated by pre-
eclampsia/eclampsia was higher than in unaffected pregnan-
cies (130% vs. 35%), and there was evidence of an
increased risk in multivariate analysis (aRR 353, 95% CI
200–264). When stratifying by SCD genotype, the risk of
pre-eclampsia/eclampsia was significantly higher in both
HbSC and HbSS pregnancies compared to non-SCD preg-
nancies (HbSC aRR 662, 95% CI 218–2008; HbSS aRR
259, 95% CI 127–529).
Induction of labour was more common in SCD pregnan-
cies compared to unaffected pregnancies (573% vs. 206%).
In adjusted analysis, there was around a threefold increased
risk of induction, with similar estimates for the combined
SCD group and also when stratified by genotype (aRR for all
SCD 290, 95% CI 240–350; aRR for HbSC 248, 95% CI
179–343; aRR for HbSS 313, 95% CI 245–400). Nearly
half (450%) of pregnancies to women with SCD ended in a
caesarean birth, with the equivalent figure for comparison
pregnancies of 327%. In adjusted analysis the risk of cae-
sarean birth was significantly higher when considering all
SCD genotypes together (aRR 144, 95% CI 118–176) and
HbSS pregnancies separately (aRR for HbSS 149, 95% CI
116–193). There was no strong evidence of an increased risk
of postpartum haemorrhage (PPH) in SCD pregnancies.
Estimates from unmatched analyses were similar to esti-
mates derived from the matched analysis (Table SII).
Discussion
In the present matched cohort study comparing singleton
pregnancies in women with SCD to unaffected pregnancies,
we found a persistently higher risk of adverse perinatal out-
comes associated with SCD. Infants born to mothers with
SCD were more likely to be SGA, born preterm and require
admission to NNU. Pregnant women with SCD were at higher
risk of pre-eclampsia/eclampsia, and more likely to receive
induction of labour, and caesarean birth. For most outcomes
of interest, risk estimates were similar for both HbSC and
HbSS pregnancies. However, there was some evidence that
both NNU admission and preterm birth were more common
in HbSS pregnancies compared to HbSC pregnancies, while
HbSC pregnancies seemed to be at greater risk of pre-
eclampsia/eclampsia compared to HbSS pregnancies.
Interpretation
Two recent meta-analyses have attempted to quantify the
excess risks associated with SCD in pregnancy.4,5 Both of
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these reviews reported a strongly increased risk of stillbirth
and maternal mortality, ranging from a two- to fivefold
increase in stillbirth, and an even higher risk of maternal
mortality. We observed one stillbirth and one maternal death
in our present cohort, both in HbSS pregnancies. Although
the incidence of stillbirth and maternal death in the SCD
Table I. Maternal characteristics by sickle cell disease (SCD) status.
Characteristic
No SCD (comparison)
(n = 1310) All SCD (n = 131) HbSC (n = 46) HbSS (n = 80)
n (%) n (%) n (%) n (%)
Age, years
<20 45 (34) 3 (23) 1 (22) 2 (25)
20–24 181 (138) 20 (153) 3 (65) 16 (200)
25–29 376 (287) 37 (282) 12 (261) 25 (313)
30–34 376 (287) 40 (305) 19 (413) 19 (238)
35–39 238 (182) 24 (183) 9 (196) 14 (175)
≥40 94 (72) 7 (53) 2 (43) 4 (50)
BMI
Underweight
Normal 38 (29) 6 (46) 0 (00) 6 (75)
Overweight 498 (380) 75 (573) 17 (370) 56 (700)
Obese 416 (318) 34 (260) 21 (457) 12 (150)
Ethnicity
Black 1310 (1000) 131 (1000) 46 (1000) 80 (1000)
Parity
0 517 (395) 55 (420) 18 (391) 36 (450)
1–2 360 (275) 42 (321) 16 (348) 25 (313)
≥3 433 (331) 34 (260) 12 (261) 19 (238)
Smoker
Yes 67 (51) 9 (69) 2 (43) 5 (63)
No 1243 (949) 122 (931) 44 (957) 75 (938)
IMD quintile
1–2 (most deprived) 1150 (878) 110 (840) 37 (804) 68 (850)
3–5 (least deprived) 160 (122) 19 (145) 9 (196) 10 (125)
Missing 0 (00) 2 (15) 0 (00) 2 (25)
Gestation at booking
<10 weeks 202 (154) 29 (221) 11 (239) 18 (225)
10–16 weeks 826 (631) 70 (534) 27 (587) 41 (513)
>16 weeks 282 (215) 23 (176) 7 (152) 15 (188)
Missing 0 (00) 9 (69) 1 (22) 6 (75)
BMI, body mass index; IMD, Index of Multiple Deprivation; SCD, sickle cell disease.
Table II. Perinatal outcome by sickle cell disease (SCD) status.
Perinatal outcome
No SCD (comparison)
(n = 1310) All SCD (n = 131) HbSC (n = 46) HbSS (n = 80)
n (%) n (%) n (%) n (%)
Stillbirth 5 (04) 1 (08) 0 (00) 1 (13)
Small for gestational age 146 (111) 26 (198) 9 (196) 17 (213)
Preterm birth (<37 weeks) 96 (73) 26 (198) 6 (130) 19 (238)
Preterm birth (<34 weeks) 36 (27) 9 (69) 2 (43) 7 (88)
Neonatal Unit admission 72 (55) 24 (183) 5 (109) 19 (238)
Pre-eclampsia/eclampsia 46 (35) 17 (130) 7 (152) 10 (125)
Induction of labour 270 (206) 75 (573) 25 (543) 47 (588)
Caesarean birth 429 (327) 59 (450) 22 (478) 35 (438)
Postpartum haemorrhage 166 (127) 19 (145) 9 (196) 10 (125)
Maternal death 0 (00) 1 (08) 0 (00) 1 (13)
SCD, sickle cell disease.
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cohort was higher than the comparison population, we did
not have sufficient events to include these outcomes in
adjusted analyses.
Poor fetal growth has long been established as a common
outcome in pregnancies complicated by SCD12 and is likely
attributable to abnormal placental development.13 In our pre-
sent study, SCD was associated with a 15–2-times higher risk
of SGA, a slightly lower risk than previously reported.4,5,14 Our
present adjusted risk estimates for preterm birth suggest a two-
to threefold increase in risk for SCD pregnancies, which is
slightly higher than in previous studies.4,5,14 Notably, the
proportion of SCD pregnancies that ended in induction of
labour was higher in our present cohort (57%) than in two
recent cohorts from the UK and North America, which
reported 39% and 22% respectively.2,14 It is possible that the
lower risk of SGA alongside a higher risk of preterm birth and
induction of labour is explained by more pro-active and cau-
tious management than in earlier studies, with a greater willing-
ness to intervene and deliver earlier in pregnancy. Compared to
infants born to mothers without SCD, we observed that infants
born to mothers with SCD were more likely to be admitted for
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Fig 2. Association between sickle cell disease
(SCD) genotype and perinatal outcome.
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of NNU admission was only statistically significant for HbSS
pregnancies. Although we were not able to identify any previ-
ous studies that reported this outcome, the increased risk of
NNU admission is unsurprising given that infants born to
women with SCD tend to be delivered at an earlier gestation.
Among preterm pregnancies, the proportion involving a NNU
admission was 54% and 44% for SCD pregnancies and non-
SCD pregnancies respectively. However, we noted that among
infants born at term, the risk of NNU admission was increased
fourfold for pregnancies affected by SCD compared to non-
SCD pregnancies (95% vs. 25%). This suggests that the
increased risk of NNU admission among SCD pregnancies is
not wholly attributable to the higher risk of preterm birth.
SCD is increasingly recognised as a risk factor for pre-
eclampsia and eclampsia.4,5,14,15 Standardised management
for the SCD cohort reported here will have included low-
dose aspirin antenatally.6 Despite this, we observed that preg-
nancies complicated by SCD had a 35-times risk of pre-
eclampsia/eclampsia. Interestingly, although HbSC is gener-
ally regarded as a less severe SCD genotype compared to
HbSS, the risk of pre-eclampsia in HbSC pregnancies was
considerably higher than in HbSS pregnancies (aRR 662 vs.
259). Mechanisms underlying the association between SCD
and pre-eclampsia are still poorly understood,16 although it
has recently been postulated that SCD may amplify placental
disease, with some suggestion that this may be irrespective of
SCD genotype and pre-pregnancy health.13
Consistent with findings from a previous review,4 we
found no evidence to support an increase in the risk of PPH
in pregnancies complicated by SCD.
Implications
The two existing meta-analyses on this topic include pregnan-
cies occurring as far back as the 1970s and 1980s. Based on
pregnancies between 2007 and 2017, the present study provides
updated evidence regarding outcomes associated with SCD in
pregnancy. With the exception of preterm birth and induction
of labour, our risk estimates were comparable or lower to
those from previous studies. It is possible that this may in part
reflect our choice of comparison group, while well-matched to
our SCD pregnancies they are also drawn from a subgroup of
pregnancies that may have a higher background risk of adverse
perinatal outcome. The fact that our present risk estimates
were comparable or lower than those from previous studies
may reflect the improvements to clinical management in preg-
nancy and non-pregnancy care that have been made over the
last 10–15 years. Early initiation of antenatal care alongside
high-quality multidisciplinary care is the cornerstone of opti-
mal management of pregnant women with SCD. It is notable
that in our present SCD cohort, the mean gestation at booking
was 135 weeks, considerably lower than the 173 weeks
observed in a study of SCD pregnancies receiving antenatal
care in the same setting between 2004 and 200817 Despite
improvements in care, pregnancy in women with SCD clearly
remains high risk, particularly for the HbSS genotype, which
is generally associated with a higher risk of adverse perinatal
outcome.5,18 Although HbSC genotype is often considered a
more benign subtype, the risk of several adverse perinatal out-
comes is also increased in HbSC pregnancies, suggesting that
close surveillance and management is just as important for
pregnant women with this genotype.2 In addition to the risk
of pregnancy-specific outcomes, sickle complications such as
vaso-occlusive pain, infections and pulmonary complications
are all observed more frequently in the pregnant SCD popula-
tion compared to the non-pregnant SCD population.19,20
Existing disease-modifying therapy for SCD is not currently
recommended in pregnancy. Previous studies have suggested
that between 30% and 70% of pregnant women with SCD
require at least one clinically indicated blood transfusion dur-
ing pregnancy,21,22 and there is increasing interest in the
potential use of chronic transfusion therapy in pregnancy. This
has shown to be an effective disease-modifying therapy in the
non-pregnant SCD population, used for primary and sec-
ondary stroke prevention and to reduce disease complications
e.g. recurrent pain and recurrent acute chest syndrome.23
However, there is insufficient evidence to support routine use
of prophylactic exchange transfusion in pregnancy,24,25
although a feasibility trial is currently ongoing.26
Strength and limitations
The strengths of the present study include the fact that we
included all singleton SCD pregnancies seen in the setting over
the time period, and we were able to select a comparable group
of pregnancies unaffected by SCD, matched on ethnic group
and year of delivery. We were able to adjust for some key
maternal characteristics, such as parity and maternal age. The
study was conducted at a centre where care was consistently
delivered according to best practice guideline, and within a uni-
versal and free at the point of access healthcare system.
SCD is a rare disease, and equally so are some of the rele-
vant perinatal outcomes. We did not have sufficient power
to examine the association between SCD and maternal or
fetal mortality. We were able to stratify results according to
the main two SCD genotypes, though small numbers impact
on the precision of our estimates, particularly for the SC
group which was smaller than the SS group. We should
therefore be cautious about assuming that a lack of signifi-
cance is synonymous with a lack of association.
Although we were able to extract data on a number of key
perinatal outcomes, the limited data available for comparison
pregnancies meant that we were unable to include several
other outcomes of interest, such as maternal antenatal and
postnatal hospital admissions, and neonatal mortality.
Conclusion
Our present findings highlight that even with best practice
contemporary management of SCD in pregnancy, the risk of
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adverse perinatal outcome is elevated. Although these risks are
seen in both major SCD genotypes, there is evidence that
pregnancies in women with HbSS are at highest risk of com-
plications, although pregnancy in women with HbSC genotype
is still associated with considerable risk. Alongside a continu-
ing focus on preconceptual counselling and early initiation of
high-quality multidisciplinary care in pregnancy for women
with SCD, further research is needed regarding the pathology
of adverse outcomes and appropriate interventions that could
further lower the risk associated with SCD in pregnancy.
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